Clinical trial
Predicting the Risk of Ovarian Cancer Recurrence Using Circulating Tumor DNA to Assess Residual Disease
NCT05212779 is registered in ClinicalTrials.gov with Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Predicting the Risk of Ovarian Cancer Recurrence Using Circulating Tumor DNA to Assess Residual Disease
- Lead sponsor
- Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
- Phase
- Observational
- Overall status
- Unknown status
- Start date
- October 7, 2022
- Completion date
- December 30, 2024
- Enrollment
- 45 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
epithelial ovarian cancer